PE20060767A1 - Derivados de tetrahidroquinolina como inhibidores de cept - Google Patents

Derivados de tetrahidroquinolina como inhibidores de cept

Info

Publication number
PE20060767A1
PE20060767A1 PE2005001475A PE2005001475A PE20060767A1 PE 20060767 A1 PE20060767 A1 PE 20060767A1 PE 2005001475 A PE2005001475 A PE 2005001475A PE 2005001475 A PE2005001475 A PE 2005001475A PE 20060767 A1 PE20060767 A1 PE 20060767A1
Authority
PE
Peru
Prior art keywords
tetrahydroquinoline derivatives
tetrahydroquinoline
cept
inhibitors
cept inhibitors
Prior art date
Application number
PE2005001475A
Other languages
English (en)
Inventor
Hilmar Bischoff
Heike Gielen-Haertwig
Carsten Schmeck
Alexandros Vakalopoulos
Martina Wuttke
Olaf Weber
Michael Thutewohl
Volkhart Li
Original Assignee
Bayer Healthcare Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE102004060997A external-priority patent/DE102004060997A1/de
Priority claimed from DE102004061000A external-priority patent/DE102004061000A1/de
Application filed by Bayer Healthcare Ag filed Critical Bayer Healthcare Ag
Publication of PE20060767A1 publication Critical patent/PE20060767A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Quinoline Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

REFERIDA A UN COMPUESTO DERIVADO DE TETRAHIDROQUINOLINA DE FORMULA I, DONDE R ES CICLOPENTILO O ISOPROPILO. TAMBIEN ESTA REFERIDA A UN PROCEDIMIENTO DE PREPARACION. DICHO COMPUESTO ES INHIBIDOR DE LA PROTEINA DE TRANSFERENCIA DE ESTER DE COLESTEROL (CETP) Y ES UTIL PARA EL TRATAMIENTO DE ENFERMEDADES CARDIOVASCULARES, DISLIPIDEMIAS, HIPERTRIGLICERIDEMIAS, ARTERIOSCLEROSIS, HIPOLIPOPROTEINEMIAS, HIPERLIPIDEMIAS E HIPERCOLESTEROLEMIAS
PE2005001475A 2004-12-18 2005-12-16 Derivados de tetrahidroquinolina como inhibidores de cept PE20060767A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102004060997A DE102004060997A1 (de) 2004-12-18 2004-12-18 Chemische Verbindung und ihre Verwendung
DE102004061000A DE102004061000A1 (de) 2004-12-18 2004-12-18 Chemische Verbindung und ihre Verwendung

Publications (1)

Publication Number Publication Date
PE20060767A1 true PE20060767A1 (es) 2006-09-10

Family

ID=35841894

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2005001475A PE20060767A1 (es) 2004-12-18 2005-12-16 Derivados de tetrahidroquinolina como inhibidores de cept

Country Status (27)

Country Link
US (2) US8124775B2 (es)
EP (1) EP1828137B1 (es)
JP (1) JP5132317B2 (es)
KR (1) KR20070090248A (es)
AR (1) AR055011A1 (es)
AT (1) ATE555097T1 (es)
AU (1) AU2005315770B2 (es)
BR (1) BRPI0519602A2 (es)
CA (1) CA2591397A1 (es)
CU (1) CU23452B7 (es)
CY (1) CY1112887T1 (es)
DK (1) DK1828137T3 (es)
DO (1) DOP2005000259A (es)
ES (1) ES2384980T3 (es)
GT (1) GT200500377A (es)
IL (1) IL184008A (es)
MA (1) MA29100B1 (es)
MX (1) MX2007007188A (es)
NO (1) NO20073146L (es)
PE (1) PE20060767A1 (es)
PL (1) PL1828137T3 (es)
PT (1) PT1828137E (es)
RU (1) RU2393151C2 (es)
SI (1) SI1828137T1 (es)
TW (1) TW200635900A (es)
UY (1) UY29276A1 (es)
WO (1) WO2006063828A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2007007187A (es) * 2004-12-18 2007-08-14 Bayer Healthcare Ag Derivados de (5s)-3-[(s)-fluoro-(4-trifluorometilfenil)metil]-5,6, 7,8-tetrahidroquinolin-5-ol y su uso como inhibidores de la proteina de transferencia de ester de colesterol.
DE102006012548A1 (de) * 2006-03-18 2007-09-20 Bayer Healthcare Ag Substituierte Chromanol-Derivate und ihre Verwendung
PL2268644T3 (pl) * 2008-03-05 2012-01-31 Boehringer Ingelheim Int Tricykliczne pochodne piperydyny, leki zawierające te związki, ich zastosowanie i sposoby ich wytwarzania
JP5780528B2 (ja) 2010-02-19 2015-09-16 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 三環式ピリジン誘導体、このような化合物を含有する医薬、それらの使用、およびそれらの調製方法
RU2572606C2 (ru) * 2010-07-09 2016-01-20 Дайити Санкио Компани, Лимитед Замещенное пиридиновое соединение
US20130053404A1 (en) 2011-02-17 2013-02-28 Boehringer Ingelheim International Gmbh Tricyclic pyridine derivatives, medicaments containing such compounds, their use and process for their preparation
AR087577A1 (es) 2011-08-17 2014-04-03 Boehringer Ingelheim Int Derivados de furo[3,4-c]quinolina, medicamentos que contienen dichos compuestos, su uso y proceso para su preparacion
ES2599757T3 (es) 2012-01-06 2017-02-03 Daiichi Sankyo Company, Limited Sales de aducto de ácido de un compuesto de piridina sustituido como inhibidores de la proteína de transferencia de ésteres de colesterilo (PTEC)
KR102456013B1 (ko) 2014-07-30 2022-10-18 에프. 호프만-라 로슈 아게 고밀도 지질단백질(hdl)-상승 제제 또는 hdl-모방 제제에 의한 치료법에 대한 반응성을 예측하기 위한 유전 표지

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19610932A1 (de) 1996-03-20 1997-09-25 Bayer Ag 2-Aryl-substituierte Pyridine
DE19627431A1 (de) 1996-07-08 1998-01-15 Bayer Ag Heterocyclisch kondensierte Pyridine
HRP970330B1 (en) * 1996-07-08 2004-06-30 Bayer Ag Cycloalkano pyridines
US6207671B1 (en) 1996-07-08 2001-03-27 Bayer Aktiengesellschaft Cycloalkano-pyridines
DE19627430A1 (de) 1996-07-08 1998-01-15 Bayer Ag Bicyclisch kondensierte Pyridine
DE19704244A1 (de) 1997-02-05 1998-08-06 Bayer Ag 5-Hydroxy-alkyl substituierte Phenyle
DE19709125A1 (de) 1997-03-06 1998-09-10 Bayer Ag Substituierte Chinoline
DE19741051A1 (de) * 1997-09-18 1999-03-25 Bayer Ag Hetero-Tetrahydrochinoline
MA24643A1 (fr) * 1997-09-18 1999-04-01 Bayer Ag Tetrahydro-naphtalenes substitues et composes analogues
DE19741399A1 (de) * 1997-09-19 1999-03-25 Bayer Ag Tetrahydrochinoline
DE19935966A1 (de) 1999-07-30 2001-02-01 Bayer Ag Verfahren zur Reduktion von Ketoalkoholen
DE10148436A1 (de) 2001-10-01 2003-04-17 Bayer Ag Tetrahydrochinoline
DE10250687A1 (de) 2002-10-31 2004-05-13 Bayer Ag 7H-Dibenzo(b,g)(1,5)dioxocin-5-on-Derivate und ihre Verwendung
MX2007007187A (es) * 2004-12-18 2007-08-14 Bayer Healthcare Ag Derivados de (5s)-3-[(s)-fluoro-(4-trifluorometilfenil)metil]-5,6, 7,8-tetrahidroquinolin-5-ol y su uso como inhibidores de la proteina de transferencia de ester de colesterol.

Also Published As

Publication number Publication date
AR055011A1 (es) 2007-08-01
US8124775B2 (en) 2012-02-28
JP5132317B2 (ja) 2013-01-30
ES2384980T3 (es) 2012-07-16
CA2591397A1 (en) 2006-06-22
AU2005315770A1 (en) 2006-06-22
US20120142728A1 (en) 2012-06-07
MX2007007188A (es) 2007-08-14
CY1112887T1 (el) 2016-04-13
RU2393151C2 (ru) 2010-06-27
IL184008A0 (en) 2007-10-31
DOP2005000259A (es) 2006-11-15
EP1828137B1 (de) 2012-04-25
EP1828137A1 (de) 2007-09-05
GT200500377A (es) 2006-11-09
UY29276A1 (es) 2006-07-31
JP2008524145A (ja) 2008-07-10
PL1828137T3 (pl) 2012-09-28
SI1828137T1 (sl) 2012-08-31
BRPI0519602A2 (pt) 2009-02-25
IL184008A (en) 2012-03-29
MA29100B1 (fr) 2007-12-03
PT1828137E (pt) 2012-07-04
AU2005315770B2 (en) 2011-12-08
RU2007127127A (ru) 2009-01-27
TW200635900A (en) 2006-10-16
KR20070090248A (ko) 2007-09-05
US20080255068A1 (en) 2008-10-16
NO20073146L (no) 2007-09-18
CU23452B7 (es) 2009-12-01
WO2006063828A1 (de) 2006-06-22
ATE555097T1 (de) 2012-05-15
DK1828137T3 (da) 2012-07-23

Similar Documents

Publication Publication Date Title
PE20060767A1 (es) Derivados de tetrahidroquinolina como inhibidores de cept
BRPI0516905A (pt) processo para a preparação de um derivado n-[2-(2-piridinil)etil]carboxamida e compostos
CY1111295T1 (el) Παραγωγα πυριμιδινης χρησιμα για τη θεραπεια ασθενειων που προκαλουνται απο crth2
TW200736221A (en) Novel pharmaceutical salts and polymorphs of a Factor Xa inhibitor
RS52823B (en) NEW UNITS USEFUL FOR TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES
PE20060525A1 (es) Compuestos heterociclicos como inhibidores de cetp
DK2032521T3 (da) Ny fremgangsmåde til saltfremstilling
EA200702541A1 (ru) Полиморфы этилового эфира 3-[(2-{[4-(гексилоксикарбониламиноиминометил)фениламино]метил}-1-метил-1н-бензимидазол-5-карбонил)пиридин-2-иламино]пропионовой кислоты
CY1109998T1 (el) Ενδυναμωτες υποδοχεων γλουταμινικου
ME01992B (me) Jedinjenje diarilhidantoina
CY1113494T1 (el) 8-ΕΤΕΡΟΑΡΥΛΟ-3-ΑΛΚΥΛΟ-1,3-ΔΙΥΔΡΟ-ΙΜΙΔΑΖΟ[4,5-c]ΚΙΝΟΛΙΝ-2-ΟΝΕΣ ΩΣ ΑΝΑΣΤΟΛΕΙΣ ΚΙΝΑΣΩΝ ΡΙ-3
WO2006052568A3 (en) Tgf-beta inhibitors
DK2301544T3 (da) Quinolinderivater som mellemprodukter til mykobakterielle inhibitorer
DE602005025251D1 (de) Verfahren zur herstellung eines 2-ethylaminopyridinderivats
EA200801341A1 (ru) КОНДЕНСИРОВАННЫЕ БИЦИКЛИЧЕСКИЕ ИНГИБИТОРЫ mTOR
ATE400567T1 (de) Kinaseinhibitoren
RS53142B (en) UNITS THAT HAVE ANTAGONISTIC ACTIVITY ON CRTH2
RS53617B1 (en) NEW UNITS USEFUL FOR TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES
MX2009003739A (es) Derivados de hidrobenzamida como inhibidores de hsp90.
WO2008062478A3 (en) Improved process for pure montelukast sodium through pure intermediates as well as novel amine salts
DE602005008953D1 (de) Substituierte chinolinderivate als inhibitoren von mitotischem kinesin
HK1159614A1 (en) Caspase inhibitors and uses thereof
SV2006002001A (es) Inhibidores de quinasa ref. x - 16437
EA200802142A1 (ru) Цинковая соль розувастатина
RS52108B (en) 3-SUBSTITUTED [1,2,3] -BENZOTRIAZINONE UNIT TO INCREASE GLUTAMATERGIC SYNAPTIC ANSWERS

Legal Events

Date Code Title Description
FC Refusal
FG Grant, registration
FD Application declared void or lapsed